Dual Control of LDL-cholesterol Levels by ANGPTL3 and ANGPTL8
This study demonstrates that while ANGPTL3 inactivation lowers lipids independently of LDL receptor secretion, the proteolytic cleavage of ANGPTL3 and the presence of ANGPTL8 are essential for differentially inhibiting lipases to further reduce LDL-cholesterol, suggesting that dual-targeted therapies could offer superior cardiovascular benefits.